Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 InvitaeElekta AB (publ)NateraCareDxVeracyte
SymbolNYSE:NVTAOTCMKTS:EKTAYNASDAQ:NTRANASDAQ:CDNANASDAQ:VCYT
Price Information
Current Price$35.32$13.75$104.93$72.89$45.31
52 Week RangeBuyHoldBuyBuyBuy
MarketRank™
Overall Score1.61.01.51.01.4
Analysis Score3.30.02.51.53.3
Community Score2.52.12.82.73.0
Dividend Score0.00.80.00.00.0
Ownership Score1.70.01.70.00.0
Earnings & Valuation Score0.61.90.60.60.6
Analyst Ratings
Consensus RecommendationBuyHoldBuyBuyBuy
Consensus Price Target$49.33N/A$113.70$75.83$66.14
% Upside from Price Target39.68% upsideN/A8.36% upside4.04% upside45.98% upside
Trade Information
Market Cap$7.40 billion$5.28 billion$9.26 billion$3.78 billion$3.23 billion
Beta2.110.851.660.840.77
Average Volume4,540,4772,979874,809777,4021,000,339
Sales & Book Value
Annual Revenue$216.82 million$1.44 billion$302.33 million$127.07 million$120.37 million
Price / Sales32.043.6630.4129.7325.22
CashflowN/A$0.62 per shareN/AN/AN/A
Price / CashN/A22.10N/AN/AN/A
Book Value$3.93 per share$2.26 per share$3.59 per share$2.33 per share$4.90 per share
Price / Book8.996.0829.2331.289.25
Profitability
Net Income$-241,960,000.00$132.74 million$-124,830,000.00$-21,970,000.00$-12,600,000.00
EPS($2.28)N/A($1.99)($0.52)($0.27)
Trailing P/E RatioN/A39.37N/AN/AN/A
Forward P/E RatioN/A29.24N/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-183.50%N/A-52.11%-11.79%-30.46%
Return on Equity (ROE)-81.19%N/A-53.39%-10.95%-12.27%
Return on Assets (ROA)-37.28%N/A-25.89%-7.94%-10.95%
Dividend
Annual PayoutN/A$0.14N/AN/AN/A
Dividend YieldN/A1.02%N/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.68%N/A0.37%N/AN/A
Current Ratio4.09%N/A4.68%4.14%26.60%
Quick Ratio4.09%N/A4.57%3.98%26.28%
Ownership Information
Institutional Ownership Percentage78.60%0.02%94.93%N/AN/A
Insider Ownership Percentage2.90%N/A9.29%3.10%8.30%
Miscellaneous
Employees2,1004,0001,815456320
Shares Outstanding196.66 million382.03 million87.63 million51.82 million67.00 million
Next Earnings Date5/4/2021 (Estimated)N/A5/5/2021 (Estimated)4/29/2021 (Estimated)5/5/2021 (Estimated)
OptionableOptionableNot OptionableOptionableOptionableOptionable
SourceHeadline
Interesting VCYT Put And Call Options For December 17th - NasdaqInteresting VCYT Put And Call Options For December 17th - Nasdaq
nasdaq.com - April 19 at 5:31 PM
Veracyte Announces Data for Pulmonology Portfolio to be Presented at American Thoracic Society 2021 International Conference - Business WireVeracyte Announces Data for Pulmonology Portfolio to be Presented at American Thoracic Society 2021 International Conference - Business Wire
businesswire.com - April 19 at 12:31 PM
Veracyte Announces Data for Pulmonology Portfolio to be Presented at American Thoracic Society 2021 International ConferenceVeracyte Announces Data for Pulmonology Portfolio to be Presented at American Thoracic Society 2021 International Conference
finance.yahoo.com - April 19 at 12:31 PM
Veracyte (NASDAQ:VCYT) Stock Price Down 10%Veracyte (NASDAQ:VCYT) Stock Price Down 10%
americanbankingnews.com - April 17 at 9:08 AM
Appointments and advancements for April 16, 2021 | 2021-04-16 - BioWorld OnlineAppointments and advancements for April 16, 2021 | 2021-04-16 - BioWorld Online
bioworld.com - April 16 at 7:20 PM
Should Biotechnology Stock Veracyte Inc (VCYT) Be in Your Portfolio Friday? - InvestorsObserverShould Biotechnology Stock Veracyte Inc (VCYT) Be in Your Portfolio Friday? - InvestorsObserver
investorsobserver.com - April 16 at 7:20 PM
Veracyte Announces Retirement of CFO and Preliminary First Quarter 2021 Financial Results - Business WireVeracyte Announces Retirement of CFO and Preliminary First Quarter 2021 Financial Results - Business Wire
businesswire.com - April 16 at 7:56 AM
Veracyte Announces Retirement of CFO and Preliminary First Quarter 2021 Financial Results - BioSpaceVeracyte Announces Retirement of CFO and Preliminary First Quarter 2021 Financial Results - BioSpace
biospace.com - April 15 at 7:51 PM
Veracyte Announces Retirement of CFO and Preliminary First Quarter 2021 Financial ResultsVeracyte Announces Retirement of CFO and Preliminary First Quarter 2021 Financial Results
finance.yahoo.com - April 15 at 7:51 PM
Needham Gives a Buy Rating to Veracyte (VCYT) - Smarter AnalystNeedham Gives a Buy Rating to Veracyte (VCYT) - Smarter Analyst
smarteranalyst.com - April 15 at 12:27 AM
Veracyte Announces Key Milestone in Companion Diagnostics Program With Acerta Pharma Using LymphMark Lymphoma Subtyping Test - BioSpaceVeracyte Announces Key Milestone in Companion Diagnostics Program With Acerta Pharma Using LymphMark Lymphoma Subtyping Test - BioSpace
biospace.com - April 15 at 12:27 AM
Veracyte Announces Key Milestone in Companion Diagnostics Program With Acerta Pharma Using LymphMark Lymphoma Subtyping Test - Business WireVeracyte Announces Key Milestone in Companion Diagnostics Program With Acerta Pharma Using LymphMark Lymphoma Subtyping Test - Business Wire
businesswire.com - April 14 at 2:26 PM
Veracyte Announces Key Milestone in Companion Diagnostics Program With Acerta Pharma Using LymphMark Lymphoma Subtyping TestVeracyte Announces Key Milestone in Companion Diagnostics Program With Acerta Pharma Using LymphMark Lymphoma Subtyping Test
finance.yahoo.com - April 14 at 9:25 AM
Veracytes (VCYT) "Buy" Rating Reaffirmed at Needham & Company LLCVeracyte's (VCYT) "Buy" Rating Reaffirmed at Needham & Company LLC
americanbankingnews.com - April 14 at 8:48 AM
Veracytes (VCYT) Buy Rating Reaffirmed at Needham & Company LLCVeracyte's (VCYT) Buy Rating Reaffirmed at Needham & Company LLC
marketbeat.com - April 14 at 7:59 AM
Is Veracyte Inc (VCYT) a Stock to Watch After Losing -1.16% This Week? - InvestorsObserverIs Veracyte Inc (VCYT) a Stock to Watch After Losing -1.16% This Week? - InvestorsObserver
investorsobserver.com - April 13 at 1:21 PM
Veracyte (NASDAQ:VCYT) Trading Up 7%Veracyte (NASDAQ:VCYT) Trading Up 7%
americanbankingnews.com - April 13 at 12:48 PM
3 Cancer Diagnostic Monster Stocks on Sale3 Cancer Diagnostic Monster Stocks on Sale
finance.yahoo.com - April 11 at 5:05 AM
Veracyte (NASDAQ:VCYT) Shares Gap Down to $53.37Veracyte (NASDAQ:VCYT) Shares Gap Down to $53.37
americanbankingnews.com - April 9 at 10:46 AM
Stocks Showing Rising Market Leadership: Veracyte Earns 84 RS Rating - Investors Business DailyStocks Showing Rising Market Leadership: Veracyte Earns 84 RS Rating - Investor's Business Daily
investors.com - April 6 at 1:02 PM
Is Veracyte Inc (VCYT) a Smart Choice in Biotechnology Monday? - InvestorsObserverIs Veracyte Inc (VCYT) a Smart Choice in Biotechnology Monday? - InvestorsObserver
investorsobserver.com - April 5 at 2:26 PM
Veracyte (NASDAQ:VCYT) Shares Gap Up to $52.72Veracyte (NASDAQ:VCYT) Shares Gap Up to $52.72
americanbankingnews.com - April 5 at 11:40 AM
Veracyte to Present at 20th Annual Needham Virtual Healthcare Conference - Yahoo FinanceVeracyte to Present at 20th Annual Needham Virtual Healthcare Conference - Yahoo Finance
finance.yahoo.com - April 2 at 8:34 AM
Veracyte to Present at 20th Annual Needham Virtual Healthcare ConferenceVeracyte to Present at 20th Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 2 at 8:34 AM
Better Buy for the Next 10 Years: Abiomed vs. Guardant Heath - NasdaqBetter Buy for the Next 10 Years: Abiomed vs. Guardant Heath - Nasdaq
nasdaq.com - April 1 at 7:24 PM
Stocks To Watch: Veracyte Sees RS Rating Jump To 82 - Investors Business DailyStocks To Watch: Veracyte Sees RS Rating Jump To 82 - Investor's Business Daily
investors.com - April 1 at 2:12 PM
DateCompanyBrokerageAction
4/11/2021InvitaeSVB LeerinkReiterated Rating
4/5/2021InvitaeOppenheimerUpgrade
2/25/2021InvitaeLADENBURG THALM/SH SHUpgrade
2/25/2021InvitaeMorgan StanleyBoost Price Target
10/14/2020InvitaeJPMorgan Chase & Co.Downgrade
7/1/2020InvitaeBenchmarkDowngrade
6/26/2020InvitaeCowenBoost Price Target
1/20/2021Elekta AB (publ)Berenberg BankReiterated Rating
1/7/2021Elekta AB (publ)Northland SecuritiesInitiated Coverage
5/7/2020Elekta AB (publ)UBS GroupDowngrade
2/21/2020Elekta AB (publ)Pareto SecuritiesDowngrade
7/16/2019Elekta AB (publ)Jefferies Financial GroupUpgrade
3/4/2021NateraPiper SandlerBoost Price Target
1/27/2021NateraTruistInitiated Coverage
1/19/2021NateraBTIG ResearchBoost Price Target
1/14/2021NateraCanaccord GenuityBoost Price Target
1/4/2021NateraCraig HallumBoost Price Target
8/6/2020NateraRobert W. BairdBoost Price Target
3/3/2021CareDxRaymond JamesLower Price Target
2/26/2021CareDxHC WainwrightDowngrade
4/14/2021VeracyteNeedham & Company LLCReiterated Rating
12/17/2020VeracyteLake Street CapitalBoost Price Target
11/9/2020VeracyteKeyCorpInitiated Coverage
11/2/2020VeracyteWilliam BlairReiterated Rating
(Data available from 4/19/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.